CEO: Martin Rosendale
Ticker: OTCQX: NUOT
Aldagen was acquired by Nuo Therapeutics in February 2012. Nuo Therapeutics is developing Aldagen’s regenerative cell therapies that target significant unmet medical needs. The company is developing and commercializing proprietary products that identify unique populations of adult stem cells that have the potential to revolutionize treatments of cancer, cardiovascular disease and other degenerative diseases.